GRN163 treatment decreased telomerase activity in human myeloma and lymphoma cell lines
Treatment . | CAG (%) . | SKO-007 (%) . | U266 (%) . | Hs602 (%) . | HT (%) . | RL (%) . | SKI-DLBCL (%) . |
|---|---|---|---|---|---|---|---|
| PBS | 166 (100) | 255 (100) | 68 (100) | 203 (100) | 248 (100) | 94 (NA) | 50 (100) |
| GRN163 1 μM | 100 (60) | 232 (91) | 38 (56) | 69 (34) | 114 (45) | 9 (10) | 10 (20) |
| GRN163 3 μM | 86 (52) | 196 (77) | 27 (40) | 29 (14) | 111 (45) | 18 (20) | NA |
| GRN163 10 μM | NA | NA | 27 (40) | NA | NA | NA | NA |
| 227 10 μM | 116 (70) | NA | 92 (100) | 170 (84) | NA | NA | NA |
Treatment . | CAG (%) . | SKO-007 (%) . | U266 (%) . | Hs602 (%) . | HT (%) . | RL (%) . | SKI-DLBCL (%) . |
|---|---|---|---|---|---|---|---|
| PBS | 166 (100) | 255 (100) | 68 (100) | 203 (100) | 248 (100) | 94 (NA) | 50 (100) |
| GRN163 1 μM | 100 (60) | 232 (91) | 38 (56) | 69 (34) | 114 (45) | 9 (10) | 10 (20) |
| GRN163 3 μM | 86 (52) | 196 (77) | 27 (40) | 29 (14) | 111 (45) | 18 (20) | NA |
| GRN163 10 μM | NA | NA | 27 (40) | NA | NA | NA | NA |
| 227 10 μM | 116 (70) | NA | 92 (100) | 170 (84) | NA | NA | NA |
Telomerase activity was measured after 14 days of GRN163 treatment. Levels are as quantified in percentage R8/NB in TRAP assay (“Patients, materials, and methods”) and are expressed as percentage of PBS-treated controls.
NA indicates not available.